• Press Release

Mount Sinai’s Natasha Kyprianou, MBBS, PhD, to Receive American Urological Association’s Richard D. Williams, MD, Prostate Cancer Research Excellence Award

The Williams Award is presented annually to recognize outstanding and impactful research in the field of prostate cancer over the past 10 years

  • New York, NY
  • (April 05, 2022)

Mount Sinai researcher Natasha Kyprianou, MBBS, PhD, a leading expert on prostate, bladder, and kidney cancer, has been awarded the Richard D. Williams, MD, Prostate Cancer Research Excellence Award by the Urology Care Foundation, the world’s leading nonprofit urological health foundation and official foundation of the American Urological Association (AUA). Dr. Kyprianou is the first woman to receive this award.

The Urology Care Foundation’s 2022 Research Awards of Distinction acknowledge outstanding contributions to urology research, specifically in pediatrics and prostate cancer, and recognize the accomplishments of previous Urology Care Foundation awardees, the dedication of exemplary research mentors, and the efforts of talented early-career scholars.

Established in 2013, the Richard D. Williams, MD, Prostate Cancer Research Excellence Award is named in honor of the late urologist, scientist, mentor, and humanitarian and is made possible through a fund established by his wife, Beverly Williams. The Williams Award is presented annually to recognize outstanding and impactful research in the field of prostate cancer over the previous 10 years.

“It is incredibly humbling to receive this award honoring the legacy of one of my heroes in Urology, Dr. Richard Williams,” said Dr. Kyprianou, who is Professor of Urology, Oncological Sciences, and Pathology, Molecular, and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai. “Knowing that my work on understanding mechanisms of therapeutic cross-resistance between taxane-based chemotherapy and antiandrogens is impacting the clinical management of patients with prostate cancer is a distinct privilege. Dr. Williams was a tremendously inspirational figure who fueled my passion for discovery of therapeutic strategies to overcome lethal prostate cancer. This award is one of the most wonderful honors of my life and a remarkable reminder that we must keep on fighting for the high cause and save lives of men suffering with prostate cancer.”

Dr. Kyprianou is a translational researcher in urologic oncology with expertise in the pathobiology of prostate, bladder, and kidney cancer, with a specific focus on dissecting mechanisms of therapeutic resistance in advanced lethal disease. Pioneering studies by Dr. Kyprianou’s team first established the novel effect of microtubule-targeting chemotherapy on the localization of the androgen receptor (AR) and activity in prostate cancer, enabling a novel insight into therapeutic cross-resistance. This paradigm shift evidence fueled a new direction of investigations in therapeutic targeting of AR by taxane-based chemotherapies.

“Dr. Kyprianou is an excellent scientist and a brilliant prostate cancer researcher who has focused her career on a prostate cancer cure,” said Ash Tewari, MBBS, MCh, Chair of Urology at the Mount Sinai Health System and the Kyung Hyun Kim, MD Professor of Urology at the Icahn School of Medicine at Mount Sinai. “We are very fortunate to work with her and are grateful for her drive to help men with lethal prostate cancer.”

"We're proud to recognize this year's Urology Care Foundation Research Awardees," said Harris M. Nagler, MD, Urology Care Foundation President. "A major component of the Foundation's mission is to support and improve urological care by funding research, and these awardees exemplify that mission through their outstanding contributions to the field of urology."

Dr. Kyprianou will receive the award at the annual AUA meeting in New Orleans on Saturday, May 14.

About the Urology Care Foundation

The Urology Care Foundation is the world's leading nonprofit urological health foundation, and the official foundation of the American Urological Association. Collaborating with physicians, researchers, patients and the public, the Foundation supports and improves urologic clinical care by funding research, developing patient education and pursuing philanthropic support. To learn more about the Urology Care Foundation and its programs visit: www.urologyhealth.org.

About the American Urological Association

Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy. www.AUAnet.org.


About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in 4 out of 10 pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.